托特罗定治疗顽固性膀胱痉挛34例

Clinical Effect of 34 Patients with Serious Bladder Spasm Treated with Tolterodine

目的 观察托特罗定治疗顽固性频繁发作膀胱痉挛的临床疗效和安全性。方法 采用随机、双盲的方法对68例膀胱痉挛频繁发作病人进行托特罗定与异搏停的对比研究,服药方法每日2次,每次托特罗定2mg或异搏停80mg。观察两组显效例数、起效时间、维持时间及不良反应。结果 托特罗定组34例中显效33例(97.1％),异搏停组34例中显效28例(82.4％)。起效时间两组差异无显著意义(P>0.05),但维持时间托特罗定组长于异搏停组,差异有显著性意义(P<0.01)。托特罗定组病人副作用发生率29％,而异搏停组发生率为87.1％,两组间差别有显著意义(P<0.01)。结论 托特罗定是治疗顽固性频繁发作膀胱痉挛的有效药物,疗效好于异搏停,且不良反应明显低于异搏停。

Objective To observe the clinical effect and safety of tolterodine on patients with serious bladder spasm. Methods A randomized,double-blind study was carried out in 68 patients with serious bladder spasm patients received either tolterodine (2mg twice daily)or isoptin (80mg twice daily). Observe the effective rate,effect-lasting time and adverse events. Results The management has been effective in 33 of 34(91. 7%)in the study group and 28 of 34(82. 4%)in the control groupGPX). 05). The mean effect-lasting time of tolterodine group was significantly higher than the isoptin group(P<0. 01). In the tolterodine group,the totel incidence of adverse event was 29%. While in the isoptin group,the incidences were 87.1%(P<0. 01). Conclusion Tolterodine had the better efficacy on patients with serious bladder spasm as compared to isoptin,and the adverse evens of tolterodine were lower than isoptin.